August 11, 2022

Cmocheat Sheets

Technology application website

Global Recombinant DNA Technology Market to Reach $841.3

18 min read
Global Recombinant DNA Technology Market to Reach $841.3

New York, June 21, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Recombinant DNA Technology Industry” – https://www.reportlinker.com/p06032744/?utm_source=GNW
8 Million in the year 2020, is projected to reach a revised size of US$841.3 Million by 2027, growing at aCAGR of 4.7% over the period 2020-2027. Medical, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$631.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Medical segment is readjusted to a revised 3.4% CAGR for the next 7-year period.
– The U.S. Market is Estimated at $179.7 Million, While China is Forecast to Grow at 4.4% CAGR
– The Recombinant DNA Technology market in the U.S. is estimated at US$179.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$148.5 Million by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Select Competitors (Total 32 Featured) –

  • Amgen Inc
  • Bamboo Therapeutics, Inc.
  • Biocon
  • Biogen
  • Chiron Corporation
  • Cibus
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • Monsanto Company
  • New England Biolabs
  • Novartis AG
  • Novo Nordisk A/S
  • Nucelis
  • Pfizer Inc.
  • Profacgen
  • Sanofi
  • Syngene

Read the full report: https://www.reportlinker.com/p06032744/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Recombinant DNA
Technology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Recombinant DNA Technology
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Recombinant DNA
Technology by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Medical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Medical by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Medical by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-Medical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Non-Medical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Non-Medical by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Expression System
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Expression System by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Expression System by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Cloning Vector by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World Historic Review for Cloning Vector by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Cloning Vector by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Health & Disease
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Health & Disease by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Health & Disease by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Food &
Agriculture by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 20: World Historic Review for Food & Agriculture by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Food & Agriculture by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Environmental by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 23: World Historic Review for Environmental by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Environmental by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Other
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 26: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Recombinant DNA Technology by
Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 30: USA 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 31: USA Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Recombinant DNA Technology by
Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 34: USA Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 35: USA Historic Review for Recombinant DNA Technology by
Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 36: USA 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

CANADA
Table 37: Canada Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Recombinant DNA Technology
by Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 39: Canada 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 40: Canada Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Recombinant DNA Technology
by Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 43: Canada Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 44: Canada Historic Review for Recombinant DNA Technology
by Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 45: Canada 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

JAPAN
Table 46: Japan Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Recombinant DNA Technology
by Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 48: Japan 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 49: Japan Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Recombinant DNA Technology
by Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 52: Japan Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 53: Japan Historic Review for Recombinant DNA Technology
by Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 54: Japan 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

CHINA
Table 55: China Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Recombinant DNA Technology
by Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 57: China 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 58: China Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Recombinant DNA Technology
by Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 61: China Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 62: China Historic Review for Recombinant DNA Technology
by Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 63: China 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

EUROPE
Table 64: Europe Current & Future Analysis for Recombinant DNA
Technology by Geographic Region – France, Germany, Italy, UK
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Recombinant DNA Technology
by Geographic Region – France, Germany, Italy, UK and Rest of
Europe Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Recombinant DNA
Technology by Geographic Region – Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Recombinant DNA Technology
by Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 69: Europe 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 70: Europe Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Recombinant DNA Technology
by Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 73: Europe Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 74: Europe Historic Review for Recombinant DNA Technology
by Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 75: Europe 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

FRANCE
Table 76: France Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Recombinant DNA Technology
by Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 78: France 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 79: France Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Recombinant DNA Technology
by Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 82: France Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 83: France Historic Review for Recombinant DNA Technology
by Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 84: France 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

GERMANY
Table 85: Germany Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Recombinant DNA
Technology by Product Type – Medical and Non-Medical Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 88: Germany Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 89: Germany Historic Review for Recombinant DNA
Technology by Type – Expression System and Cloning Vector
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 90: Germany 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 91: Germany Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 92: Germany Historic Review for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

ITALY
Table 94: Italy Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 95: Italy Historic Review for Recombinant DNA Technology
by Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 96: Italy 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 97: Italy Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 98: Italy Historic Review for Recombinant DNA Technology
by Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 99: Italy 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 100: Italy Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 101: Italy Historic Review for Recombinant DNA Technology
by Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 102: Italy 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 103: UK Current & Future Analysis for Recombinant DNA
Technology by Product Type – Medical and Non-Medical –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 104: UK Historic Review for Recombinant DNA Technology by
Product Type – Medical and Non-Medical Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 105: UK 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 106: UK Current & Future Analysis for Recombinant DNA
Technology by Type – Expression System and Cloning Vector –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 107: UK Historic Review for Recombinant DNA Technology by
Type – Expression System and Cloning Vector Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 108: UK 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 109: UK Current & Future Analysis for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications – Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 110: UK Historic Review for Recombinant DNA Technology by
Application – Health & Disease, Food & Agriculture,
Environmental and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 111: UK 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 112: Rest of Europe Current & Future Analysis for
Recombinant DNA Technology by Product Type – Medical and
Non-Medical – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 113: Rest of Europe Historic Review for Recombinant DNA
Technology by Product Type – Medical and Non-Medical Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 114: Rest of Europe 15-Year Perspective for Recombinant
DNA Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 115: Rest of Europe Current & Future Analysis for
Recombinant DNA Technology by Type – Expression System and
Cloning Vector – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: Rest of Europe Historic Review for Recombinant DNA
Technology by Type – Expression System and Cloning Vector
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 117: Rest of Europe 15-Year Perspective for Recombinant
DNA Technology by Type – Percentage Breakdown of Value Sales
for Expression System and Cloning Vector for the Years 2012,
2020 & 2027

Table 118: Rest of Europe Current & Future Analysis for
Recombinant DNA Technology by Application – Health & Disease,
Food & Agriculture, Environmental and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 119: Rest of Europe Historic Review for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 120: Rest of Europe 15-Year Perspective for Recombinant
DNA Technology by Application – Percentage Breakdown of Value
Sales for Health & Disease, Food & Agriculture, Environmental
and Other Applications for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 121: Asia-Pacific Current & Future Analysis for
Recombinant DNA Technology by Product Type – Medical and
Non-Medical – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 122: Asia-Pacific Historic Review for Recombinant DNA
Technology by Product Type – Medical and Non-Medical Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 123: Asia-Pacific 15-Year Perspective for Recombinant DNA
Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 124: Asia-Pacific Current & Future Analysis for
Recombinant DNA Technology by Type – Expression System and
Cloning Vector – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 125: Asia-Pacific Historic Review for Recombinant DNA
Technology by Type – Expression System and Cloning Vector
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 126: Asia-Pacific 15-Year Perspective for Recombinant DNA
Technology by Type – Percentage Breakdown of Value Sales for
Expression System and Cloning Vector for the Years 2012, 2020 &
2027

Table 127: Asia-Pacific Current & Future Analysis for
Recombinant DNA Technology by Application – Health & Disease,
Food & Agriculture, Environmental and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 128: Asia-Pacific Historic Review for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 129: Asia-Pacific 15-Year Perspective for Recombinant DNA
Technology by Application – Percentage Breakdown of Value Sales
for Health & Disease, Food & Agriculture, Environmental and
Other Applications for the Years 2012, 2020 & 2027

REST OF WORLD
Table 130: Rest of World Current & Future Analysis for
Recombinant DNA Technology by Product Type – Medical and
Non-Medical – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 131: Rest of World Historic Review for Recombinant DNA
Technology by Product Type – Medical and Non-Medical Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 132: Rest of World 15-Year Perspective for Recombinant
DNA Technology by Product Type – Percentage Breakdown of Value
Sales for Medical and Non-Medical for the Years 2012, 2020 &
2027

Table 133: Rest of World Current & Future Analysis for
Recombinant DNA Technology by Type – Expression System and
Cloning Vector – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 134: Rest of World Historic Review for Recombinant DNA
Technology by Type – Expression System and Cloning Vector
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 135: Rest of World 15-Year Perspective for Recombinant
DNA Technology by Type – Percentage Breakdown of Value Sales
for Expression System and Cloning Vector for the Years 2012,
2020 & 2027

Table 136: Rest of World Current & Future Analysis for
Recombinant DNA Technology by Application – Health & Disease,
Food & Agriculture, Environmental and Other Applications –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 137: Rest of World Historic Review for Recombinant DNA
Technology by Application – Health & Disease, Food &
Agriculture, Environmental and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 138: Rest of World 15-Year Perspective for Recombinant
DNA Technology by Application – Percentage Breakdown of Value
Sales for Health & Disease, Food & Agriculture, Environmental
and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 32
Read the full report: https://www.reportlinker.com/p06032744/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


        
cmocheatsheets.com © All rights reserved. | Newsphere by AF themes.